Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study

Lignende værker

• Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study
  af: He ZY, et al.
  Udgivet: (2019-03-01)
• EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
  af: Dong, Kai, et al.
  Udgivet: (2019)
• First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
  af: Chen, Yongshun, et al.
  Udgivet: (2016)
• Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
  af: Zhao, Lihao, et al.
  Udgivet: (2019)
• Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases
  af: Kim, Michelle M., et al.
  Udgivet: (2016)